| scholarly article | Q13442814 |
| P2093 | author name string | Robert P Myers | |
| Abdel Aziz M Shaheen | |||
| P2860 | cites work | APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C | Q79852758 |
| Non-invasive models for predicting histology in patients with chronic hepatitis B | Q79910299 | ||
| Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis | Q79972021 | ||
| Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index | Q80042859 | ||
| Natural history of hepatitis C | Q80384219 | ||
| Insulin resistance as a non-invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods | Q83884051 | ||
| The Combination of Estimates from Different Experiments | Q100745541 | ||
| Conducting systematic reviews of diagnostic studies: didactic guidelines | Q24797459 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews | Q29619492 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data | Q30703091 | ||
| HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease | Q33227070 | ||
| Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. | Q33235606 | ||
| New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples | Q33266698 | ||
| HIV-related thrombocytopenia | Q33341657 | ||
| Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B | Q33787916 | ||
| Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests | Q33806407 | ||
| Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy | Q33866383 | ||
| Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers | Q33867515 | ||
| The diagnostic odds ratio: a single indicator of test performance | Q34276416 | ||
| Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. | Q34326379 | ||
| Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations | Q34342972 | ||
| Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group | Q34349755 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection | Q34438649 | ||
| Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 | ||
| A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. | Q34560349 | ||
| Controversies in liver biopsy: who, where, when, how, why? | Q35628105 | ||
| Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes | Q35760270 | ||
| Development and validation of methods for assessing the quality of diagnostic accuracy studies | Q35802603 | ||
| A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure | Q35914841 | ||
| Current and future concepts in hepatitis C therapy | Q36054696 | ||
| Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. | Q36109458 | ||
| Noninvasive measures of liver fibrosis | Q36382285 | ||
| Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group | Q36596005 | ||
| Identifying relevant studies for systematic reviews | Q36888457 | ||
| Classification of chronic viral hepatitis: a need for reassessment | Q37032966 | ||
| Progression of liver fibrosis among injection drug users with chronic hepatitis C. | Q40339820 | ||
| Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers | Q42994550 | ||
| A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy | Q43032664 | ||
| Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies | Q43875837 | ||
| Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. | Q44003646 | ||
| Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model | Q44151781 | ||
| A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. | Q44527614 | ||
| Meta-analysis of diagnostic test accuracy assessment studies with varying number of thresholds | Q44767951 | ||
| The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. | Q44785887 | ||
| Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index | Q44880241 | ||
| Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? | Q44880294 | ||
| Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection | Q45411335 | ||
| Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. | Q45411339 | ||
| Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection | Q45417576 | ||
| Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients | Q45421063 | ||
| Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. | Q45422802 | ||
| Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study | Q45737816 | ||
| Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? | Q45859625 | ||
| Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index | Q46490993 | ||
| Comparative study of two models that use biochemical parameters for the non-invasive diagnosis of fibrosis in patients with hepatitis C | Q46519780 | ||
| A novel panel of blood markers to assess the degree of liver fibrosis | Q46827711 | ||
| The importance of aminotransferases and platelets count in non-invasive evaluation stages of chronic hepatitis C | Q46878904 | ||
| Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. | Q46951830 | ||
| Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. | Q46953851 | ||
| Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis | Q46990919 | ||
| The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. | Q47372679 | ||
| Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin | Q47732710 | ||
| Sampling variability of liver fibrosis in chronic hepatitis C. | Q48583601 | ||
| Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. | Q51927013 | ||
| Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients | Q51982985 | ||
| Serum markers detect the presence of liver fibrosis: a cohort study | Q51983072 | ||
| Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors | Q51990048 | ||
| Chronic hepatitis. An update on terminology and reporting | Q53635198 | ||
| Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis | Q58621814 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 912-921 | |
| P577 | publication date | 2007-09-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review | |
| P478 | volume | 46 |
| Q28742875 | A Secreted Form of the Asialoglycoprotein Receptor, sH2a, as a Novel Potential Noninvasive Marker for Liver Fibrosis |
| Q35724652 | A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection |
| Q27488742 | A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients |
| Q30472903 | A new scoring system for prediction of fibrosis in chronic hepatitis C. |
| Q40966087 | A novel glycobiomarker, Wisteria floribunda agglutinin macrophage colony-stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis. |
| Q33843701 | A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension |
| Q30375134 | A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C |
| Q36664042 | AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis |
| Q43657166 | Access to treatment of hepatitis C in prison inmates |
| Q46793741 | Accuracy and reliability of microbubble ultrasound measurements for the non‐invasive assessment of hepatic fibrosis in chronic hepatitis C |
| Q30453975 | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver |
| Q35100139 | An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver |
| Q39574494 | Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray |
| Q40790849 | Aspartate aminotransferase to platelet ratio index - a reliable predictor of therapeutic efficacy and improvement of Ishak score in chronic hepatitis B patients treated with nucleoside analogues. |
| Q35565542 | Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection |
| Q30472899 | Aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis severity in patients with chronic hepatitis. |
| Q35540294 | Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease |
| Q37199708 | Assessment of liver disease (noninvasive methods) |
| Q47551529 | Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C. |
| Q83099911 | Back to the future with noninvasive biomarkers of liver fibrosis |
| Q37323789 | Biomarkers of liver fibrosis |
| Q37825547 | Biomarkers of liver fibrosis |
| Q37897194 | Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? |
| Q33756904 | Biopsychosocial factors associated with pain in veterans with the hepatitis C virus |
| Q46104385 | Causes of death in patients with hepatitis B: A natural history cohort study in the United States |
| Q58622691 | Chapter 4 Biomarkers Of Liver Fibrosis |
| Q26825671 | Chronic hepatitis C and liver fibrosis. |
| Q41545044 | Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study |
| Q83721888 | Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI) |
| Q36566930 | Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects |
| Q39018477 | Commentary on: Aspartate transaminase to platelet ratio index (APRI): A simple noninvasive index assessing liver fibrosis in patients with chronic liver diseases |
| Q45158767 | Comparing the Aspartate Aminotransferase (AST) to Platelet Ratio Index (APRI) Between African American and White Veterans with Chronic Hepatitis C |
| Q50976613 | Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis |
| Q40315812 | Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir |
| Q39447596 | Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis |
| Q38240784 | Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis |
| Q51509141 | Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. |
| Q42272013 | Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration |
| Q38540088 | Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis |
| Q37278212 | Demographics of a large cohort of urban chronic hepatitis C patients |
| Q54234625 | Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies |
| Q26779866 | Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis |
| Q42264092 | Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C. |
| Q34158701 | Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis |
| Q59351982 | Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study |
| Q36770544 | Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels |
| Q34168383 | EASL Clinical Practice Guidelines: Management of hepatitis C virus infection |
| Q42177206 | ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity |
| Q43034449 | Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea |
| Q30470750 | Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis |
| Q94602713 | Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index |
| Q39244103 | Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection |
| Q37627015 | Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. |
| Q46831361 | FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. |
| Q28077200 | Hepatic steatosis and fibrosis: Non-invasive assessment. |
| Q39237214 | Hepatitis A to E: what's new? |
| Q34659484 | Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma. |
| Q43046834 | How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? |
| Q34345002 | Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia |
| Q42182001 | Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load |
| Q33749894 | Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers |
| Q33819963 | Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q36532141 | Liver Damage in Patients with HCV/HIV Coinfection Is Linked to HIV-Related Oxidative Stress |
| Q37014193 | Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C |
| Q38759277 | Liver Fibrosis: Causes and Methods of Assessment, A Review |
| Q93046532 | Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography |
| Q50594991 | Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation |
| Q46232074 | Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study |
| Q82910548 | Management of hepatitis C in patients with chronic kidney disease |
| Q37313574 | Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update |
| Q37037079 | Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus |
| Q38032835 | Molecular serum markers of liver fibrosis. |
| Q42160967 | Non-biopsy methods to determine hepatic fibrosis. |
| Q88855656 | Non-invasive Assessment of Liver Fibrosis with ElastPQ: Comparison with Transient Elastography and Serologic Fibrosis Marker Tests, and Correlation with Liver Pathology Results |
| Q37613375 | Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease |
| Q42406716 | Non-invasive assessment of liver fibrosis |
| Q30474738 | Non-invasive assessment of liver fibrosis in chronic hepatitis C |
| Q40915287 | Non-invasive assessment of liver fibrosis using acoustic structure quantification: comparison with transient elastography in chronic viral hepatitis. |
| Q43086324 | Non-invasive assessment of liver fibrosis: are we ready? |
| Q37801658 | Non-invasive assessment of liver fibrosis: it is time for laboratory medicine |
| Q85623588 | Non-invasive diagnosis of liver fibrosis |
| Q26778033 | Non-invasive diagnosis of liver fibrosis and cirrhosis |
| Q43210156 | Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: a comparative analysis of nine scoring methods. |
| Q27000645 | Non-invasive prediction of forthcoming cirrhosis-related complications. |
| Q30877287 | Non-invasive score system for fibrosis in chronic hepatitis: proposal for a model based on biochemical, FibroScan and ultrasound data |
| Q35458645 | Non-invasive serum fibrosis markers: A study in chronic hepatitis. |
| Q45102502 | Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort |
| Q36049926 | Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection |
| Q57173225 | Noninvasive biomarkers in NAFLD and NASH - current progress and future promise |
| Q30401743 | Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis |
| Q41416623 | Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. |
| Q30464087 | Noninvasive tools to assess hepatic fibrosis: ready for prime time? |
| Q37868672 | Non‐invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence |
| Q45896181 | Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children |
| Q51092816 | Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B. |
| Q37313577 | Other non-invasive markers of liver fibrosis |
| Q85201097 | Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine |
| Q30459104 | Performance of liver stiffness measurements by transient elastography in chronic hepatitis. |
| Q35859323 | Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitis |
| Q37841383 | Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §Δ |
| Q37146827 | Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections |
| Q33402861 | Portal Hypertension in Children and Young Adults With Biliary Atresia |
| Q37605578 | Postoperative aspartate aminotransferase to platelet ratio index change predicts prognosis for hepatocellular carcinoma |
| Q37468027 | Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers |
| Q47114292 | Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis |
| Q30374727 | Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. |
| Q42284225 | Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C |
| Q64092011 | Predictive value of the aspartate aminotransferase to platelet ratio index for parenteral nutrition associated cholestasis in extremely low birth weight infants |
| Q34001628 | Predictors of pain intensity and pain functioning in patients with the hepatitis C virus |
| Q34423936 | Preserved MHC-II antigen processing and presentation function in chronic HCV infection |
| Q58693832 | Prognostic value of aspartate aminotransferase to platelet ratio index as a noninvasive biomarker in patients with hepatocellular carcinoma: a meta-analysis |
| Q35791614 | Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy |
| Q30380023 | Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study |
| Q38229320 | Recurrent HCV after liver transplantation-mechanisms, assessment and therapy |
| Q50445732 | Red cell volume distribution width-to-platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. |
| Q39940215 | Reference Intervals of Fibrosis Index Based on Four Indicators in Healthy Elderly Chinese. |
| Q53076537 | Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. |
| Q37726058 | Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. |
| Q37355850 | Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies |
| Q43185894 | Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection |
| Q38074087 | Role of liver biopsy in the era of direct-acting antivirals. |
| Q34385138 | Role of simple biomarkers in predicting fibrosis progression in HCV infection |
| Q51848337 | SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. |
| Q30358956 | Serum Glycopatterns as Novel Potential Biomarkers for Diagnosis of Acute-on-Chronic Hepatitis B Liver Failure |
| Q35149315 | Serum NX-DCP as a New Noninvasive Model to Predict Significant Liver Fibrosis in Chronic Hepatitis C. |
| Q34395035 | Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C |
| Q42695116 | Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. |
| Q51278552 | Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. |
| Q35594262 | Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence |
| Q33612264 | Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study |
| Q37727315 | Surgical outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma for various resection extent |
| Q37063803 | Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection |
| Q36643026 | Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease |
| Q88293218 | The Effect of Underlying Liver Disease on Perioperative Outcomes Following Craniotomy for Tumor: An American College of Surgeons National Quality Improvement Program Analysis |
| Q26786170 | The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis |
| Q35195470 | The effect of antiviral therapy on serum cholesterol levels in chronic hepatitis C |
| Q36989440 | The impact of human immune deficiency virus and hepatitis C coinfection on white matter microstructural integrity |
| Q44595693 | The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases |
| Q55288229 | The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. |
| Q43112745 | The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. |
| Q35000910 | The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women |
| Q42240534 | The validity of serum markers for fibrosis staging in chronic hepatitis B and C. |
| Q26998730 | Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis |
| Q41711121 | Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. |
| Q45149873 | Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers |
| Q34417027 | Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study |
| Q34926896 | Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. |
| Q40959924 | Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study |
| Q38916843 | Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. |
| Q36555228 | Use of the AST to platelet ratio index in HCV/HIV co‐infected patients |
| Q58798449 | Usefulness of aspartate aminotransferase to platelet ratio index as a prognostic factor following hepatic resection for hepatocellular carcinoma |
| Q84385952 | Utility of liver function tests including aminotransferase-to-platelet ratio index in monitoring liver dysfunction in short-gut infants of varying ages and intestinal lengths |
| Q42208113 | Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns' index in chronic hepatitis C virus |
| Q40557601 | Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis |
| Q54570262 | WITHDRAWN: Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. |
| Q36720968 | What is the real function of the liver 'function' tests? |
| Q84919708 | [Liver fibrosis : clinics, diagnostics and management] |
| Q58622697 | Évaluation non-invasive de la fibrose hépatique au cours de l’hépatite C |
Search more.